Forecast

Buy	2
Hold	1
Sell	0

News Go to news feed

SINTX reports strong revenue growth in Q2 2026, stock falls after hours

SINTX recorded a 199% revenue increase in the second quarter of 2026 to $452,000 and improved its gross margin to 61.5%, while net loss widened to $2.7 million. The company reported initial commercial revenues for the SINAPTIC-Wedge system and orders from contract manufacturing customers of about $3.2 million. The stock finished the regular session slightly higher but declined after hours as investors weighed continued losses, high cash burn (cash $3.6 million) and doubts about the company’s ability to continue as a going concern. Management guidance sees revenue of $0.9–1.1 million for Q3 2026 and $1.0–1.3 million for Q4, and the company emphasized additional financing needs and ongoing execution risks. » More on de.investing.com
SINTX signs supply agreement with EVONIK for SiN/PEEK composite for AI-assisted 3D printing manufacturing

SINTX Technologies has signed a supply agreement with Evonik for the industrial production of its patented silicon nitride‑PEEK (SiN/PEEK) composite for AI‑assisted additive manufacturing of patient‑specific implants. Evonik will produce the scalable composite filament to SINTX specifications, enabling SINTX to begin immediate manufacture of 3D‑printed vertebral body replacement implants and other indications. SINTX highlights the material’s antipathogenic surface properties, osteogenic potential and improved imaging, and intends to use it to support regulatory approvals and humanitarian applications. » More on finanzen.net
SINTX Technologies closes private-label deal for OsseoSculpt and plans market launch

SINTX Technologies has signed a private-label agreement to supply the biologic OsseoSculpt, intended to complement the FDA‑cleared SINAPTIC Foot & Ankle Osteotomy Wedge System. The company reports initial commercial revenue from OsseoSculpt in Q3 2025 and plans a limited rollout at early‑adopter sites with a broader US launch in Q1 2026. In parallel, SINTX received 510(k) clearance for the SINAPTIC wedge system, a Notice of Allowance for an anti‑pathogenic silicon nitride technology, and raised about $3.8 million through option exercises, but remains under profitability pressure with negative EBITDA and sharply declining revenues. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, SINTX Technologies Inc has already paid 4,56€ in dividends. The last payout was in June 2023.

Financials

In the last quarter, SINTX Technologies Inc had revenue of 396.05k€ and net profit of −2.37m€

(EUR)	Jun 2026	YoY
Revenue	+396.05k	366,81%
Gross profit	+243.59k	4.685,10%
Net profit	−2.37m	20,56%
EBITDA	−2.31m	26,32%

Fundamentals

Metric	Value
Market capitalization	+8.35m€
Number of shares	6.36m
52-week high/low	+5,82€ - +1,20€
Dividends	No
Beta	0,64
P/E ratio	−0,28
PEG ratio	0,00
P/B ratio	+1,54
P/S ratio	+7,04

Company profile

Sintx Technologies, Inc. ist ein Unternehmen für hochentwickelte Materialien, das sich mit der Erforschung, Entwicklung und Vermarktung von medizinischen Geräten beschäftigt, die mit Siliziumnitrid für biomedizinische, industrielle und antipathogene Anwendungen hauptsächlich in den Vereinigten Staaten hergestellt werden. Das Unternehmen bietet festes und poröses Siliziumnitrid, Siliziumnitrit-Pulver und Siliziumnitrid-Beschichtungsprodukte sowie Siliziumnitrid-Verbundwerkstoffe und Polyetherketonketon an. Das Unternehmen war früher unter dem Namen Amedica Corporation bekannt. Sintx Technologies, Inc. wurde 1996 gegründet und hat seinen Hauptsitz in Salt Lake City, Utah.